Teva Pharmaceutical Industries' efforts to streamline its manufacturing processes as it reshapes its destiny over the next several years haven't stopped progress on what is termed the world's largest over-the-counter manufacturing facility.
Teva Pharmaceuticals ($TEVA) has money in the bank, drugs in the pipeline and big plans for the future. Given those assets and four more years, CEO Jeremy Levin told investors on Tuesday they will have a whole new Teva.
Manufacturing shortcomings have cost another top executive her job.
Generics giant Teva Pharmaceutical Industries ($TEVA) and Procter & Gamble ($PG) announced the creation of their joint venture in consumer healthcare that they first discussed in March. PGT
Hoping to "spark a renaissance in American manufacturing," President Barack Obama is putting up $500 million for the U.S. to "remain a nation that invents it here and manufactures it here." And
Procter & Gamble's plan to ride Teva's manufacturing expertise shows just how valuable a manufacturing operation can be. That's not to say that the ops boost for P&G is the essence of the
Teva Pharmaceutical Industries is joining the parade of drugmakers looking to pump up in consumer healthcare. The Israeli company has teamed up with Procter & Gamble in a joint venture, which
Here's a test case for you: Procter & Gamble is launching a social media initiative for Prilosec as part of its bid to maintain the drug's leadership position in an increasingly crowded market.
Procter & Gamble has been cited for the illegal marketing of combinations of dietary ingredients and drugs. P&G products Vicks DayQuil Plus Vitamin C and Vicks Nyquil Plus Vitamin C lack
Late last year, Proctor & Gamble decided that it wanted out of the pharmaceuticals business. Its drug unit--which features drugs in the areas of women's health, gastrointestinal problems and